Cargando…
Current and Potential Therapies Targeting Inflammation in NASH
Nonalcoholic steatohepatitis (NASH) is the advanced form of nonalcoholic fatty liver disease (NAFLD). It is characterized by hepatic steatosis, inflammation, hepatocellular injury, and fibrosis. Inflammation plays a key role in the progression of NASH and can be provoked by intrahepatic (e.g., lipot...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8678040/ https://www.ncbi.nlm.nih.gov/pubmed/34925237 http://dx.doi.org/10.3389/fendo.2021.767314 |
_version_ | 1784616265981100032 |
---|---|
author | Albhaisi, Somaya Noureddin, Mazen |
author_facet | Albhaisi, Somaya Noureddin, Mazen |
author_sort | Albhaisi, Somaya |
collection | PubMed |
description | Nonalcoholic steatohepatitis (NASH) is the advanced form of nonalcoholic fatty liver disease (NAFLD). It is characterized by hepatic steatosis, inflammation, hepatocellular injury, and fibrosis. Inflammation plays a key role in the progression of NASH and can be provoked by intrahepatic (e.g., lipotoxicity, immune responses, oxidative stress and cell death) and extrahepatic sources (adipose tissue or gut). The identification of triggers of inflammation is central to understanding the mechanisms in NASH development and progression and in designing targeted therapies that can halt or reverse the disease. In this review, we summarize the current and potential therapies targeting inflammation in NASH. |
format | Online Article Text |
id | pubmed-8678040 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-86780402021-12-18 Current and Potential Therapies Targeting Inflammation in NASH Albhaisi, Somaya Noureddin, Mazen Front Endocrinol (Lausanne) Endocrinology Nonalcoholic steatohepatitis (NASH) is the advanced form of nonalcoholic fatty liver disease (NAFLD). It is characterized by hepatic steatosis, inflammation, hepatocellular injury, and fibrosis. Inflammation plays a key role in the progression of NASH and can be provoked by intrahepatic (e.g., lipotoxicity, immune responses, oxidative stress and cell death) and extrahepatic sources (adipose tissue or gut). The identification of triggers of inflammation is central to understanding the mechanisms in NASH development and progression and in designing targeted therapies that can halt or reverse the disease. In this review, we summarize the current and potential therapies targeting inflammation in NASH. Frontiers Media S.A. 2021-12-03 /pmc/articles/PMC8678040/ /pubmed/34925237 http://dx.doi.org/10.3389/fendo.2021.767314 Text en Copyright © 2021 Albhaisi and Noureddin https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Endocrinology Albhaisi, Somaya Noureddin, Mazen Current and Potential Therapies Targeting Inflammation in NASH |
title | Current and Potential Therapies Targeting Inflammation in NASH |
title_full | Current and Potential Therapies Targeting Inflammation in NASH |
title_fullStr | Current and Potential Therapies Targeting Inflammation in NASH |
title_full_unstemmed | Current and Potential Therapies Targeting Inflammation in NASH |
title_short | Current and Potential Therapies Targeting Inflammation in NASH |
title_sort | current and potential therapies targeting inflammation in nash |
topic | Endocrinology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8678040/ https://www.ncbi.nlm.nih.gov/pubmed/34925237 http://dx.doi.org/10.3389/fendo.2021.767314 |
work_keys_str_mv | AT albhaisisomaya currentandpotentialtherapiestargetinginflammationinnash AT noureddinmazen currentandpotentialtherapiestargetinginflammationinnash |